Trial Profile
A Dose Double-blind,Placebo-controlled,Single Dosing,Dose-escalation Clinical Trial to Investigate the Safety,Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Beta lapachone (Primary)
- Indications Macular degeneration; Metabolic syndrome; Non-alcoholic fatty liver disease; Obesity
- Focus Adverse reactions
- Sponsors KT&G Life Sciences
- 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 07 Feb 2011 New trial record